Surgery and Clinical Practice
Open AccessKinesiology Taping After Tissue-Expander Breast Reconstruction: A Randomized Single-Blind Pilot Trial
Authors: Alfredo Chama-Naranjo, Fernando Barbosa-Villarreal, Arturo Reyes-Esparza, Daniel Garza Arriaga, Cuauhtemoc Marquez Espriella, Rodrigo Davila Diaz, Marco Antonio Cuervo Vergara, Ana Priscila Campollo Lopez.
Abstract
Background:
Immediate tissue-expander breast reconstruction may be followed by pain, edema,
upper-limb dysfunction, and scarrelated concerns that complicate postoperative
recovery. Kinesiology taping (KT) is a low-cost, noninvasive adjunct, but
evidence in this surgical setting remains limited.
Objective:
To assess the feasibility, safety, and exploratory clinical outcomes of a
standardized KT protocol after immediate unilateral tissue-expander breast
reconstruction.
Methods:
This randomized single-blind pilot trial was conducted at two tertiary referral
hospitals from May 2023 to July 2024. Thirtyfour women undergoing immediate
tissue-expander reconstruction were allocated to KT plus routine postoperative
care (n=17) or routine postoperative care alone (n=17). Pilot domains included
feasibility, adherence, retention, protocol completion, and adverse events.
Exploratory outcomes included pain, DASH/QuickDASH, Vancouver Scar Scale, limb
circumference and volume, drainage outcomes, grip strength, and FACT-B.
Results:
All 34 randomized participants were included in the available analysis. KT was
associated with lower pain scores during the first four postoperative weeks
(p<0.005), improved DASH scores during the first three weeks (p<0.001),
and better Vancouver Scar Scale scores from week 3 onward (p<0.001). Limb
circumference and volume were reduced after four weeks (p=0.012 and p=0.015), but
these differences were not maintained at 1-month follow-up (p>0.05). Grip
strength, QuickDASH, and FACT-B did not differ significantly between groups
(p>0.05).
Conclusion:
Standardized KT appeared feasible and showed exploratory short-term benefits
after immediate tissue-expander breast reconstruction. Larger prospectively
registered trials are needed.